• Discreet packaging
  • Results 24-48h
  • Home delivery and collection
  • No appointments, no waiting
  • Accredited laboratories
  • Discreet packaging
  • Results 24-48h
  • Home delivery and collection
  • No appointments, no waiting
  • Accredited laboratories
  • Discreet packaging
  • Results 24-48h
  • Home delivery and collection
  • No appointments, no waiting
  • Accredited laboratories
  • Discreet packaging
  • Results 24-48h
  • Home delivery and collection
  • No appointments, no waiting
  • Accredited laboratories
Our Tests
For professionals
Activate Kit

SOLUTIONS FOR PHARMACEUTICAL LABORATORIES

Transforming awareness into clinical evidence

Talk to our team
sanofi-logo-2022 - copy
merck 1
boehringer 1
sanofi-logo-2022 - copy (2)
merck-2
boehringer-2

Action on key pathologies and direct doctor-patient connection

Designs awareness programmes that integrate minimally invasive testing, personalised education for clinicians and patients, and a seamless digital experience, maximising engagement and generating clinical evidence

Generates real-world evidence (RWE) to demonstrate clinical impact

Raising awareness among doctors and patients on key pathologies and biomarkers

Identifies under-diagnosed populations

Working with patient associations and other actors to reach out to those most in need

Designs decentralised clinical studies to increase reach and impact

SOLUTIONS FOR PHARMACEUTICAL LABORATORIES

Comprehensive diagnostic solutions in a single ecosystem

Evidence accessible from anywhere

CE and IVD marked kits designed for easy and guided sampling. We take care of collection, shipment to the laboratory, analysis and interpretation of results.

Scientific rigour in every analysis

Samples are analysed in certified laboratories in our network. We integrate with new laboratories and health systems following health interoperability standards.

Accompanying the patient every step of the way

The patient is guided at all times by our app: kit activation, sample collection and access to results with an experience designed to understand their health in a clear way.

Simple clinical management at scale

Platform designed to scale patient management and personalised report delivery, keeping clinical control in the hands of the clinician at all times

AI trained by and for doctors

An artificial intelligence layer created in conjunction with physicians that converts lab data into structured clinical reports, ready for medical review.

Real-time health evidence

Anonymised results turned into population and longitudinal health analytics to improve prevention, research and decision making with our network of partners

Ready-to-integrate tests

Type 1 diabetes

What we measure
  • HbA1c
  • IAA
  • GADA
  • IA-2A
  • ZnT8A

More information

Cardiovascular monitoring

What we measure
  • Lp(a)
  • LDL
  • HDL
  • Triglycerides
  • 1 more

More information

Renal profile

What we measure
  • Glomerular Filtration
  • Creatinine
  • Albumin

More information

How we work with health leaders

Health education with practical application and impact on the population

See more

Awareness raising in collaboration with patient associations

See more

Comprehensive T1D screening platform for professionals and patients

See more

Design your solution with Ailin today

Type 1 diabetes

  • Family background
  • Autoimmune diseases

We assess the risk of developing type 1 diabetes (T1D) by measuring the main associated autoantibodies and glycaemic profile, using a minimally invasive capillary finger prick test, both inside and outside the clinical setting.

It allows the implementation of screening campaigns in populations at higher risk of T1D, including first-degree relatives and people with associated autoimmunity.

In addition, analysis of multiple autoantibodies and metabolic biomarkers allows segmentation of risk populations and the generation of real-world evidence (RWE) in longitudinal cohorts across successive programmes.

  • Minimally invasive tests
  • Structured consent management and traceability
  • Results in 7-14 days
  • Clinical interpretation included
  • Digital platform ready to integrate
Request for information

Cardiovascular monitoring

  • Family background
  • Cardiometabolic health

We assess cardiovascular risk by determining the main lipid biomarkers (total cholesterol, HDL, LDL and triglycerides) and Lp(a), using a minimally invasive capillary finger prick test, both inside and outside the clinical setting.

It allows the implementation of screening campaigns in populations at increased cardiometabolic risk, including people with a family history and/or associated risk factors.

The combined analysis of lipid biomarkers and Lp(a) facilitates risk stratification and the generation of real-world evidence (RWE) in population-based cohorts through successive programmes.

  • Minimally invasive tests
  • Structured consent management and traceability
  • Results in 5-7 days
  • Clinical interpretation included
  • Digital platform ready to integrate
Request for information

Renal profile

  • Family background
  • Diabetes

Chronic kidney disease (CKD) can progress silently for years, making early detection key. Our programmes assess kidney function by determining key biomarkers - creatinine, glomerular filtration rate, and albumin/creatinine ratio - through a minimally invasive test using capillary puncture and urine sampling, both inside and outside the clinical setting.

It allows screening campaigns to be implemented in populations at higher risk of CKD, including people with diabetes, hypertension, cardiovascular disease or those over 60 years of age.

Structured analysis of renal biomarkers allows the generation of aggregated population screening data and enables longitudinal follow-up tools, facilitating the evaluation of the impact of early detection programmes.

  • Minimally invasive tests
  • Structured consent management and traceability
  • Results in 5 days
  • Clinical interpretation included
  • Digital platform ready to integrate
Request for information

Health education with practical application and impact on the population

The challenge

One of the main challenges for the pharmaceutical industry is to support the continuing clinical education of healthcare professionals, generating a real connection that goes beyond theoretical information and facilitates the incorporation of new biomarkers into clinical practice.

Our solution

We collaborate with pharmaceutical companies in the design and deployment of awareness programmes at international medical congresses, offering a hands-on experience that allows professionals to be guided through the entire patient journey.

Through a digital infrastructure, participants understand how the biomarker is integrated into the care process, from detection to clinical interpretation, in a real environment and applicable to their daily practice.

The impact

We have participated in more than 30 international medical congresses, such as EASD, ATTD or ISPAD, in collaboration with global pharmaceutical organisations, generating spaces for scientific awareness and high-impact clinical conversation.

Request for information

Awareness-raising and early detection together with patient associations

The challenge

Many pathologies remain underdetected in the general population due to lack of information and access to simple tests. Patient organisations play a key role in raising awareness and supporting people, but bringing this work to the field requires an infrastructure to do so rigorously, safely and at scale.

The solution

Ailin collaborates with patient associations to design and deploy awareness and early detection campaigns aimed at the general population. The associations define the focus and target audience, and Ailin provides the diagnostic infrastructure, operational capacity and clinical support needed to execute the initiatives.

This model brings screening tests closer to the public, connects people with patient associations and, where necessary, directs them to the appropriate care pathway.

The impact

We have developed campaigns in different public settings in several provinces of Spain, carrying out thousands of renal function measurements using capillary blood and urine (creatinine, eGFR and albumin/creatinine ratio).

These initiatives have contributed to raising awareness, facilitating early detection and connecting people with the relevant patient associations, reinforcing their support and accompaniment work.

Request for information

Type 1 diabetes screening platform for professionals and patients

The challenge

The implementation of population-based screening programmes, such as type 1 diabetes (T1D), is an operational and healthcare challenge for health systems. For these programmes to be sustainable and scalable, it is essential to have an infrastructure that supports healthcare professionals, reduces the administrative burden and accompanies participants throughout the process.

The solution

Ailin has developed a comprehensive platform, designed together with healthcare professionals, to manage DT1 screening programmes from start to finish. The platform centralises and standardises all stages of the process: selection of participants, structured collection of clinical information, traceability of samples, organised visualisation of results and subsequent follow-up.

From a clinical point of view, the system offers a global and prioritised view of the participants, organising the results according to the context of each case. This helps to optimise the healthcare professional's time, reduce administrative tasks and facilitate clear and consistent communication.

In addition to clinical support, the platform guides the participant through the entire process, providing clear information at each stage, facilitating kit activation and offering explained results that reduce doubts and improve adherence.

The impact

This infrastructure, developed in collaboration with public and private entities, has made it possible to analyse T1D-associated biomarkers (IAA, IA-2A, GADA, ZnT8A) and HbA1c in more than 3,500 people, facilitating high-volume screening programmes with clinical rigour.

Throughout 2026, this approach will be expanded through new partnerships with healthcare organisations to bring early diagnosis of type 1 diabetes to populations at higher risk, allowing these programmes to be scaled up without compromising the system's capacity to deliver care.

Request for information

Account

Explore

Whatsapp Instagram Linkedin Youtube
Why do we include it in this test?

 .

What other tests are you undergoing?
Discount coupon of 5% available: #ADS05
10% discount coupon available: AILINSOCIAL